Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 968

1.

Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.

Kinon BJ, Basson BR, Gilmore JA, Tollefson GD.

J Clin Psychiatry. 2001 Feb;62(2):92-100.

PMID:
11247108
[PubMed - indexed for MEDLINE]
2.

Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.

Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD.

J Clin Psychiatry. 2001 Apr;62(4):231-8.

PMID:
11379836
[PubMed - indexed for MEDLINE]
3.

Weight gain during treatment of bipolar I patients with olanzapine.

Hennen J, Perlis RH, Sachs G, Tohen M, Baldessarini RJ.

J Clin Psychiatry. 2004 Dec;65(12):1679-87.

PMID:
15641874
[PubMed - indexed for MEDLINE]
4.

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.

Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, Lieberman JA.

Am J Psychiatry. 2003 Feb;160(2):290-6.

PMID:
12562575
[PubMed - indexed for MEDLINE]
5.

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.

Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM; HGDH Study Group.

Am J Psychiatry. 2003 Aug;160(8):1396-404.

PMID:
12900300
[PubMed - indexed for MEDLINE]
6.

Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.

Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, Chakos M, McEvoy JP.

J Clin Psychiatry. 2002 Oct;63(10):931-5.

PMID:
12416603
[PubMed - indexed for MEDLINE]
7.

[Prescription of olanzapine in children and adolescent psychiatric patients].

Frémaux T, Reymann JM, Chevreuil C, Bentué-Ferrer D.

Encephale. 2007 Mar-Apr;33(2):188-96. Review. French.

PMID:
17675914
[PubMed - indexed for MEDLINE]
8.
9.

Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.

Tran PV, Dellva MA, Tollefson GD, Beasley CM Jr, Potvin JH, Kiesler GM.

J Clin Psychiatry. 1997 May;58(5):205-11. Erratum in: J Clin Psychiatry 1997 Jun;58(6):275.

PMID:
9184614
[PubMed - indexed for MEDLINE]
10.

Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.

Tollefson GD, Beasley CM Jr, Tamura RN, Tran PV, Potvin JH.

Am J Psychiatry. 1997 Sep;154(9):1248-54.

PMID:
9286184
[PubMed - indexed for MEDLINE]
11.

Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder.

Andersen SW, Clemow DB, Corya SA.

J Clin Psychiatry. 2005 Nov;66(11):1468-76.

PMID:
16420086
[PubMed - indexed for MEDLINE]
12.

Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study.

Bobes J, Rejas J, Garcia-Garcia M, Rico-Villademoros F, García-Portilla MP, Fernández I, Hernández G; EIRE Study Group.

Schizophr Res. 2003 Jul 1;62(1-2):77-88.

PMID:
12765747
[PubMed - indexed for MEDLINE]
13.

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.

Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME.

Am J Psychiatry. 1997 Apr;154(4):457-65.

PMID:
9090331
[PubMed - indexed for MEDLINE]
14.

Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.

Simpson MM, Goetz RR, Devlin MJ, Goetz SA, Walsh BT.

J Clin Psychiatry. 2001 Sep;62(9):694-700.

PMID:
11681765
[PubMed - indexed for MEDLINE]
15.

Olanzapine versus haloperidol treatment in first-episode psychosis.

Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley C Jr, Tollefson GD.

Am J Psychiatry. 1999 Jan;156(1):79-87.

PMID:
9892301
[PubMed - indexed for MEDLINE]
16.

A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.

Perez-Iglesias R, Crespo-Facorro B, Amado JA, Garcia-Unzueta MT, Ramirez-Bonilla ML, Gonzalez-Blanch C, Martinez-Garcia O, Vazquez-Barquero JL.

J Clin Psychiatry. 2007 Nov;68(11):1733-40.

PMID:
18052567
[PubMed - indexed for MEDLINE]
17.

Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.

Saddichha S, Ameen S, Akhtar S.

J Clin Psychopharmacol. 2008 Feb;28(1):27-31. doi: 10.1097/jcp.0b013e3181602fe6.

PMID:
18204337
[PubMed - indexed for MEDLINE]
18.

Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses.

Melkersson KI, Hulting AL, Brismar KE.

J Clin Psychiatry. 2000 Oct;61(10):742-9.

PMID:
11078035
[PubMed - indexed for MEDLINE]
19.

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.

Conley RR, Mahmoud R.

Am J Psychiatry. 2001 May;158(5):765-74. Erratum in: Am J Psychiatry 2001 Oct;158(10):1759.

PMID:
11329400
[PubMed - indexed for MEDLINE]
20.

Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol.

Zipursky RB, Gu H, Green AI, Perkins DO, Tohen MF, McEvoy JP, Strakowski SM, Sharma T, Kahn RS, Gur RE, Tollefson GD, Lieberman JA.

Br J Psychiatry. 2005 Dec;187:537-43.

PMID:
16319406
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk